

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Year Ended December 31,	
	2017	2016
Grant and collaboration revenue	\$ 1,075	\$ 828
Operating expenses:		
Research and development	2,017	1,971
General and administrative	1,232	2,131
	3,249	4,102
Loss from operations	(2,174)	(3,274)
Interest income	4	2
Net loss	\$ (2,170)	\$ (3,272)
Net loss per common share	\$ (0.03)	\$ (0.08)
Weighted average shares outstanding	68,606	41,517

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	December 31,	
	2017	2016
Assets:		
Cash and cash equivalents	\$ 313	\$ 454
Other current assets	135	90
Total current assets	448	544
Property, net	31	55
Other assets	11	11
Total assets	\$ 490	\$ 610
Liabilities and stockholders' equity		
Current liabilities	\$ 811	\$ 370
Stockholders' equity (deficiency)	(321)	240
Total liabilities and stockholders' equity	\$ 490	\$ 610
Common Shares Outstanding	106,737	55,235